Related Experiment Video
Updated: Aug 21, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma
Da-Xiong Zeng1, Chang-Guo Wang1, Wei Lei1
1Department of Respiratory and Critical Care, The First Affiliated Hospital of Soochow University, Suzhou, China.
Abstract:
Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients without driver mutation. However, few drugs could be selected when diseases progressed after second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib was suggested mainly using in advanced gastric cancer. In this study, we showed the results of apatinib as second-line to fourth-line treatment in EGFR wild-type advanced lung adenocarcinoma patients. 16 EGFR wild-type advanced lung adenocarcinoma patients were administrated apatinib (250-500 mg/d) orally. 3 patients showed partial response and 8 patients showed stable diseases response to apatinib, with a medium progression-free survival (PFS) of 4.4 month (2-10 months). The objective remission rate (ORR) was 18.75%(3/16). The total disease control rate (DCR) was 68.75% (11/16). The main toxicities were hypertension, hand-foot syndrome, proteinuria and thrombocytopenia which were tolerable and manageable. So, apatinib might be an optional choice for post-first-line treatment of EGFR wild-type advanced lung adenocarcinoma patients.
Insights
Apatinib shows promise for advanced lung adenocarcinoma patients without driver mutations. This study found apatinib offers a disease control rate of 68.75% in EGFR wild-type patients after initial treatments.
Area of Science:
- Oncology
- Pharmacology
Background:
- Chemotherapy is standard for advanced lung adenocarcinoma without driver mutations.
- Limited treatment options exist after second-line therapy progression.
- Apatinib, a VEGFR-2 inhibitor, is primarily used for gastric cancer.
Purpose of the Study:
- To evaluate apatinib's efficacy and safety as a second- to fourth-line treatment.
- To assess apatinib in EGFR wild-type advanced lung adenocarcinoma patients.
Main Methods:
- 16 EGFR wild-type advanced lung adenocarcinoma patients received oral apatinib (250-500 mg/d).
- Treatment was administered as second-line to fourth-line therapy.
- Efficacy endpoints included objective remission rate (ORR) and disease control rate (DCR).
Main Results:
- Partial response in 3 patients, stable disease in 8.
- Median progression-free survival (PFS) was 4.4 months.
- Objective remission rate (ORR) was 18.75%; disease control rate (DCR) was 68.75%.
Conclusions:
- Apatinib demonstrated a 68.75% disease control rate in this patient group.
- Main toxicities (hypertension, hand-foot syndrome) were manageable.
- Apatinib may be a viable option for post-first-line treatment in EGFR wild-type advanced lung adenocarcinoma.
